Otezla® (apremilast) – Expanded indication
July 23, 2025 - The FDA approved Amgen’s Otezla (apremilast), for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis.
July 23, 2025 - The FDA approved Amgen’s Otezla (apremilast), for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis.